Immunotherapy in colorectal cancer: rationale, challenges and potential

Karuna Ganesh^{1*}, Zsafia K. Stadler¹, Andrea Cercek¹, Robin B. Mendelsohn¹, Jinru Shia², Neil H. Segal¹ and Luis A. Diaz Jr¹

Abstract | Following initial successes in melanoma treatment, immunotherapy has rapidly become established as a major treatment modality for multiple types of solid cancers, including a subset of colorectal cancers (CRCs). Two programmed cell death 1 (PD1)-blocking antibodies, pembrolizumab and nivolumab, have shown efficacy in patients with metastatic CRC that is mismatch-repair-deficient and microsatellite instability-high (dMMR–MSI-H), and have been granted accelerated FDA approval. In contrast to most other treatments for metastatic cancer, immunotherapy achieves long-term durable remission in a subset of patients, highlighting the tremendous promise of immunotherapy in treating dMMR–MSI-H metastatic CRC. Here, we review the clinical development of immune checkpoint inhibition in CRC leading to regulatory approvals for the treatment of dMMR–MSI-H CRC. We focus on new advances in expanding the efficacy of immunotherapy to early-stage CRC and CRC that is mismatch-repair-proficient and has low microsatellite instability (pMMR–MSI-L) and discuss emerging approaches for targeting the immune microenvironment, which might complement immune checkpoint inhibition.

Colorectal cancer (CRC) is a major cause of cancer death worldwide. In developed countries, early detection through screening has improved the 5-year survival of patients with CRC, but ~25% of patients still present with stage 4 disease, and a further 25–50% present with early-stage disease but go on to develop metastatic disease^{1–4}. The prognosis for patients with metastatic CRC (mCRC) remains poor, with a median 5-year survival of only 12.5% in the USA². Thus, the development of more effective treatments for patients with this disease is an urgent unmet need. In the past decade, immunotherapy has elicited tremendous excitement owing to its success in achieving long-term durable responses in previously difficult-to-treat solid tumours, such as melanoma and lung cancer. High tumour mutation burden has emerged as a marker of responsiveness to immunotherapy in several tumour types^{5,6}. In CRC, immune checkpoint therapy received regulatory approval in 2017 for the treatment of heavily mutated tumours that are mismatch-repair-deficient (dMMR) or have high levels of microsatellite instability (MSI-H) (termed dMMR–MSI-H tumours). By contrast, current immune checkpoint inhibitors (ICIs) are ineffective in tumours that are mismatch-repair-proficient (pMMR) and are microsatellite-stable (MSS) or have low levels of microsatellite instability (MSI-L) (termed pMMR–MSI-L tumours). In these tumours, low tumour mutation

burden and the lack of immune cell infiltration have been posited as mechanisms of immune resistance^{7,8}. In this Review, we describe the rationale for using immunotherapy in select patients with mCRC, discuss available clinical data supporting its use and highlight current clinical approaches and future directions for expanding the scope of immunotherapy in CRC.

Rationale for immunotherapy in CRC

In CRC, T cell infiltration into the tumour bed has long been associated with favourable outcomes, suggesting a possible role for immunoediting in controlling tumour growth^{9,10}. The immune system distinguishes self from non-self through the binding of T cell receptors (TCR) on T cells to complexes of peptides with major histocompatibility complex (MHC) class I molecules presented on the surface of all cells, including tumour cells^{11,12}. Recognition of peptide–MHC class I complexes by the TCR alone is insufficient for T cell activation. TCR–MHC signalling pathways are modulated by co-stimulatory or co-inhibitory signals, which tumour cells exploit to escape destruction^{13–15}. ICIs target co-inhibitory receptors, such as cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed cell death 1 (PD1) on T cells and other immune cell subpopulations, or their ligands, such as programmed cell death 1 ligand 1 (PDL1) on tumour cells and various immune cells.

¹Department of Medicine, Memorial Sloan Kettering Cancer Center, York Avenue, New York, NY, USA.

²Department of Pathology, Memorial Sloan Kettering Cancer Center, York Avenue, New York, NY, USA.

*e-mail: ganeshk@mskcc.org

<https://doi.org/10.1038/s41575-019-0126-x>

Key points

- Colorectal cancer (CRC) can be categorized into tumours that are mismatch-repair-deficient or have high levels of microsatellite instability (dMMR–MSI-H; ~15%) and mismatch-repair-proficient or microsatellite instability-low tumours (pMMR–MSI-L; ~85%).
- dMMR–MSI-H CRC is associated with a high tumour mutation burden and immune cell infiltration.
- Immune checkpoint inhibitor (ICI) treatment, specifically with monoclonal antibodies targeting programmed cell death 1 (PD1) and cytotoxic T lymphocyte antigen 4 (CTLA4), results in improved survival in metastatic dMMR–MSI-H CRC, but pMMR–MSI-L CRC is largely unresponsive to current ICIs.
- The FDA has granted accelerated approval to the anti-PD1 antibodies pembrolizumab and nivolumab and to the combination of nivolumab with the anti-CTLA4 antibody ipilimumab for treatment of refractory dMMR–MSI-H CRC.
- Clinical evaluation of ICIs in first-line metastatic, adjuvant and neoadjuvant settings and in combination with other therapies and research into improved prognostic and predictive biomarkers of ICI response and improved activity in pMMR–MSI-L CRC are ongoing.
- Beyond PD1 blockade, monospecific and bispecific antibodies, cellular therapies, vaccines and cytokines targeting other immune checkpoint molecules, macrophages and other components of innate immunity are under active investigation.

Thus, ICIs prevent T cell dysfunction and apoptosis and instead enhance T cell activation, potentiating cytotoxic killing of tumour cells (FIG. 1).

ICIs were first shown to improve survival in metastatic melanoma and subsequently in non-small-cell lung cancer (NSCLC), leading to FDA approvals for ipilimumab (targeting CTLA4) and pembrolizumab and nivolumab (targeting PD1) for the treatment of these solid tumours^{16–24}. Importantly, long-term follow-up data showed that a subset of patients survived for ≥10 years after ipilimumab treatment²⁰. As the potential of immunotherapy to achieve long-term durable responses in some advanced solid tumours was recognized, the need for biomarkers that could distinguish tumours that did or did not respond to immunotherapy became apparent. In a study of the mutational landscapes of human cancer, melanoma and NSCLC were the cancer types with the highest prevalence of mutations²⁵. The correlation between mutation prevalence and immunotherapy response suggested that tumour cells with high mutation burdens generate and present more peptide neoantigens on their MHC class I molecules; thus, these tumours are more likely to be recognized as non-self, in turn priming T cells for activation and cytotoxic killing^{26,27}.

dMMR–MSI-H and pMMR–MSI-L CRC

CRC can be categorized into two discrete groups on the basis of mutation patterns: tumours that have a dMMR–MSI-H signature and high overall mutation burden (>12 mutations per 10⁶ DNA bases) and tumours that have a pMMR–MSI-L signature with a much lower mutation burden (<8.24 mutations per 10⁶ DNA bases)²⁸. Defective DNA mismatch repair (MMR) can be detected either by the lack of immunohistochemical staining of the MMR proteins MLH1, MSH2, MSH6 or PMS2 or by PCR-identified alterations in the lengths of microsatellites between a patient's tumour and a sample of normal tissue or blood. In the past 5 years, computational analyses of tumour next-generation sequencing

were also shown to accurately detect microsatellite instability (MSI) status (mSINGS²⁹, MSIsensor^{30,31} and MOSAIC³²). Assessment for dMMR–MSI-H was initially used to identify patients in whom further germline testing for Lynch syndrome was warranted³³. MSI-H is the hallmark of tumours in patients with Lynch syndrome, but the development of dMMR–MSI-H is a sporadic event in ~70–85% of all patients with dMMR–MSI-H tumours owing to somatic defects in MMR gene function, most commonly hypermethylation of the *MLH1* promoter. Importantly, dMMR–MSI-H tumours are heavily infiltrated by immune cells, notably CD8⁺ tumour-infiltrating lymphocytes (TILs), T helper 1 (T_H1) CD4⁺ TILs and macrophages, and have a microenvironment that is rich in type I interferons in comparison with other CRCs^{7,34–42} (BOX 1; FIG. 2). However, the extent to which these two features overlap has not been rigorously investigated, and clinical trials investigating ICIs in CRC have not specifically utilized TILs as a predictive biomarker.

Approximately 15% of all CRCs are dMMR–MSI-H⁴³. Presence of dMMR–MSI-H disease is prognostic, as stage 2 dMMR–MSI-H tumours have a lower risk of recurrence than stage 2 pMMR–MSI-L tumours, with a hazard ratio for overall survival associated with MSI of 0.65 (95% CI 0.59–0.71) in pooled analysis⁴⁴. Accordingly, stage 4 dMMR–MSI-H tumours constitute only ~2–4% of all mCRCs. Patients with dMMR–MSI-H tumours that metastasize have a dismal prognosis⁴⁵, but expression of PD1, PDL1 and CTLA4 is substantially upregulated in their cancers³⁹. These observations suggested that dMMR–MSI-H CRCs might respond well to immune checkpoint blockade.

Immunotherapy for dMMR–MSI-H CRC

Studies resulting in immune checkpoint inhibitor approval. In initial studies published between 2010 and 2013, ICIs demonstrated very limited clinical activity in nonselected CRC. An anti-CTLA4 immunoglobulin G2 (IgG2) antibody, tremelimumab, was evaluated in 45 patients with treatment-refractory CRC and resulted in a partial response in 1 individual, but the MMR status of this patient was not known⁴⁶. In a phase I study of BMS-936559, an anti-PDL1 antibody, in refractory solid tumours, no responses were observed⁴⁷. Nivolumab, an anti-PD1 antibody, was evaluated in 19 patients, and initially, no responses were reported⁴⁸; however, 1 of the patients had a response at 21 months, and after re-treatment, this patient achieved a complete response that lasted ≥3 years^{49,50}. This patient had dMMR–MSI-H CRC.

On the basis of the knowledge of the immunogenic microenvironment of MSI-H tumours and the observed impressive tumour response, enthusiasm for immunotherapy in CRC grew, and several studies investigated the therapeutic potential of PD1 inhibitors. A phase II trial (NCT01876511) of the anti-PD1 antibody pembrolizumab was reported in 2015, in which three separate cohorts of patients were treated: dMMR–MSI-H CRCs, pMMR–MSI-L CRCs and dMMR–MSI-H non-CRCs⁵¹. Of the 10 patients with dMMR–MSI-H CRC, 4 had a partial response and 5 had stable disease at 20 weeks. At this time point, the median progression-free survival (PFS)

Fig. 1 | Targets of currently FDA-approved immune checkpoint inhibitors.

Endogenous peptides are processed and presented on major histocompatibility complex (MHC) class I molecules on the surface of all human cells, including cancer cells. The peptide–MHC complex is recognized by T cell receptors (TCRs). The response of the T cell is fine-tuned by a range of co-inhibitory or co-stimulatory signals. The ligands CD28 and CD86 of the B7 family of membrane-bound ligands can bind to the co-stimulatory CD28 and, especially in activated T cells, to cytotoxic T lymphocyte antigen 4 (CTLA4). Similarly, membrane-bound programmed cell death 1 ligand 1 (PDL1) and programmed cell death 1 ligand 2 (PDL2) can engage programmed cell death 1 (PD1), leading to T cell anergy and/or apoptosis. Monoclonal antibodies that bind to either the inhibitory receptors on T cells or their cognate ligands on cancer cells antagonize inhibitory signalling and enable T cell activation and cytotoxic tumour cell killing. Currently, FDA-approved immune checkpoint inhibitors target CTLA4 (ipilimumab), PD1 (pembrolizumab and nivolumab) and PDL1 (atezolizumab and durvalumab). Pembrolizumab and nivolumab, as well as the combination of nivolumab and ipilimumab, are currently approved for colorectal cancer in the USA.

and overall survival were not yet reached in the dMMR–MSI-H cohort but were 2.2 months and 5.0 months, respectively, in the pMMR–MSI-L cohort (HR for disease progression or death 0.10 ($P < 0.001$); HR for death 0.22 ($P = 0.05$)). In updated results presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, the response rate was 50% (95% CI 31–69%), and the disease control rate was 89% in the 28 patients with dMMR–MSI-H tumours. At 24 months, PFS was 61%, and overall survival was 66%⁵². None of the 18 patients with pMMR–MSI-L CRC responded. This study demonstrated the benefit of immune checkpoint blockade in dMMR–MSI-H tumours. Analyses demonstrated that the number of somatic mutations significantly correlated with the chance of achieving a response to therapy ($P = 0.02$)⁸. Furthermore, results from an expansion of this study published in 2017 across 12 tumour types demonstrated that pembrolizumab was effective in dMMR tumours regardless of tissue of origin⁸.

In CheckMate 142 (NCT02060188), another PD1 inhibitor, nivolumab, was tested in 74 patients with dMMR–MSI-H mCRC⁵³. Study results were first published in 2017. At a median follow-up duration of 12 months, 23 (31%) patients achieved an investigator-assessed objective response, and in 51 (69%) patients, disease control for ≥ 12 weeks was observed. The median PFS was 14.3 months (95% CI 4.3 months to not estimable), and the 12-month PFS was 50% (95% CI 38–61%). The 12-month overall survival was 73% (95% CI 62–82%). Combination of nivolumab with ipilimumab was also evaluated in this trial^{54,55}.

Of 30 patients enrolled, 9 patients (33%) achieved an objective response, and 14 patients (52%) achieved stable disease. Updated results of CheckMate 142 in the complete cohort of 119 patients with a median follow-up duration of 13.4 months demonstrated an objective response rate of 55% and tumour burden reduction from baseline in 77% of patients^{54,55}. At this time point, the median PFS was not yet reached, and the 9-month and 12-month PFS values were 76% (95% CI 67.0–82.7%) and 71% (95% CI 61.4–78.7%), respectively. The median overall survival was not reached, and the 9-month and 12-month overall survival values were 87% (95% CI 80.0–92.2%) and 85% (95% CI 77.0–90.2%), respectively. Treatment with combined nivolumab and ipilimumab resulted in an increased rate of drug-related immune-related adverse events: 32% of patients experienced grade 3–4 treatment-related adverse events compared with 20% of patients treated with nivolumab alone⁵⁴ (BOX 2). On the basis of the compelling data in dMMR–MSI-H CRCs, the FDA granted accelerated approval to pembrolizumab in May 2017 and to nivolumab in July 2017 for the second-line treatment of patients with dMMR–MSI-H CRC. To date, no drug or combination has been granted approval by the European Medicines Agency (EMA), pending results of phase III randomized controlled studies.

Current and future studies. Multiple studies are ongoing to evaluate PD1 or PDL1 inhibition in dMMR–MSI-H CRC with the potential of practice-changing results (TABLE 1). Results of the phase II trial Checkmate 142 evaluating the efficacy and safety of combined nivolumab and low-dose ipilimumab therapy in previously untreated patients with stage 4 dMMR–MSI-H CRC were reported at the 2018 European Society for Medical Oncology (ESMO) Annual Meeting⁵⁶. In 45 enrolled patients followed-up for a median of 13.8 months, the objective response rate and disease control rate were 60% and 84%, respectively; 7% of patients had a complete response. PFS and overall survival values at 12 months were 77% and 83%, respectively, and the extent of treatment-related adverse events were acceptable⁵⁶. Keynote-177 is a phase III trial (NCT02563002) evaluating first-line pembrolizumab in stage 4 dMMR–MSI-H CRC⁵⁷. As of May 2018, 308 patients were enrolled to be randomly allocated to pembrolizumab or investigator's choice of first-line chemotherapy. The primary end points are PFS and overall survival, and the secondary end point is overall response rate. A further study in the first-line setting is underway (NCT02997228)⁵⁸. In this trial, 347 patients are planned to be randomly allocated to the anti-PDL1 antibody atezolizumab, first-line combination chemotherapy (comprising 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) plus the vascular endothelial growth factor antagonist bevacizumab) or the combination of both treatments. The primary trial end point is PFS, and secondary end points include overall survival and objective response rate.

Immunotherapy for pMMR–MSI-L CRC

Unlike in patients with dMMR–MSI-H CRC, immunotherapy alone has not demonstrated a clinical benefit in patients with pMMR–MSI-L CRC, who constitute the vast majority of patients with mCRC. In the pivotal

Box 1 | Innate immunity in cancer sensing and immunotherapy

In addition to T cells, innate immune cells, such as macrophages, dendritic cells and natural killer cells, also infiltrate the microenvironment of mismatch-repair-deficient and microsatellite instability-high (dMMR–MSI-H) colorectal cancer (CRC) tumours^{42,140,141}. Similar to tumour-infiltrating lymphocytes, a high proportion of tumour-associated macrophages (TAMs) expresses programmed cell death 1 (PD1)¹⁴¹. In mice bearing CT26 dMMR–MSI-H CRC xenografts, PD1⁺ TAMs displayed reduced tumour phagocytosis compared with PD1[−] macrophages, but treatment with checkpoint inhibitors targeting PD1 or programmed cell death 1 ligand 1 (PDL1) increased phagocytosis and reduced tumour growth¹⁴¹. In a study in MC38 dMMR–MSI-H CRC tumour-bearing mice, in vivo imaging showed that anti-PD1 antibodies were sequestered by TAMs in an Fcγ receptor-dependent manner¹⁴². In turn, blockade of Fcγ receptors inhibited anti-PD1 sequestration and improved the response rate. These observations highlight that macrophages have important functions in modulating immunotherapy responses and suggest opportunities for therapeutic intervention.

The endoplasmic reticulum protein stimulator of interferon genes (STING) is required for type I interferon signalling following detection of cytosolic DNA of exogenous and endogenous origin¹⁴³. In the presence of cytosolic DNA, the cytoplasmic nucleotidyl transferase cGAS catalyses cyclic GMP–AMP (GAMP) formation, which binds and activates STING¹⁴³. The STING pathway can be activated within antigen-presenting cells in the tumour microenvironment, subsequently driving T cell priming against tumour-associated antigens. In mice lacking STING, CD8⁺ T cell priming against tumours is defective, leading to an inability to reject immunogenic tumours¹⁴⁴. Alteration in DNA damage responses through DNA-damaging chemotherapy or loss of normal DNA repair capacity can further contribute to STING activation and antitumour immunity¹⁴⁵. The STING pathway seems to be a major mechanism for innate immune sensing of cancers and might provide a possibility to potentiate the effects of cancer immunotherapy. Early-phase clinical trials employing human STING agonists are currently underway in patients with advanced and/or metastatic solid tumours or lymphomas to investigate this hypothesis (NCT02675439 (REF.¹⁴⁶), NCT03010176 (REF.¹⁴⁷) and NCT03172936 (REF.¹⁴⁸)).

pembrolizumab study, no responses were observed in patients with pMMR–MSI-L tumours⁵¹, consistent with the lack of efficacy of immunotherapy in early studies with nonselected patients, most of whom had pMMR–MSI-L tumours. In the Check Mate 142 study, limited responses were seen in pMMR–MSI-L tumours: 1 of 20 patients responded to combination therapy with antibodies blocking PD1 and CTLA4 (REF.⁵⁴). The lack of recruitment of immune cells to the tumour seems to be the fundamental obstacle to efficacy. Combination treatment of PD1 inhibitors and modulators of other immune checkpoint molecules, such as CTLA4, might be beneficial in a small subset of patients with pMMR–MSI-L tumours, but alternative approaches of immune modulation are required for the majority of patients with this CRC subtype.

MEK and PDL1 inhibition. Preclinical data suggest several opportunities for combination therapy. In addition to direct pro-proliferative effects on tumour cells, activation of the RAS–MAPK pathway has been associated with decreased T cell infiltration into tumours; conversely, in preclinical models, inhibition of MEK, a downstream effector of this pathway, induced IFNγ-dependent HLA and PDL1 upregulation and synergized with PD1 inhibition to augment antitumour activity^{59,60}. On the basis of these data, a phase I study (NCT01988896) of the MEK inhibitor cobimetinib and PDL1 inhibition with atezolizumab was initiated⁶¹. The study includes an expansion cohort of patients with KRAS-mutant CRC, and of the 23 patients enrolled when preliminary data were reported in 2016, 4 patients (17%) had a partial response. Three of

the four responders had confirmed pMMR–MSI-L CRC, and the status of the other patient is unknown. Updated results were presented in 2018, showing a tolerable safety profile and partial responses in 7 of 84 patients enrolled (8%; 3 pMMR–MSI-L, 1 MSI-L and 3 unknown status) at a median follow-up duration of 14.3 months⁶². These exciting data led to a phase III randomized trial of cobimetinib plus atezolizumab versus atezolizumab only or regorafenib in patients with refractory pMMR–MSI-L CRC (NCT02788279)⁶³. However, in results reported at the 2018 ESMO World Congress on Gastrointestinal Cancer, the study failed to meet its primary end point: atezolizumab and cobimetinib combination therapy and atezolizumab monotherapy failed to demonstrate statistically significant prolonged overall survival compared with regorafenib⁶⁴. Ongoing studies of combining immunotherapy and targeted therapy in patients with pMMR–MSI-L CRC include a phase II study of combined cobimetinib, nivolumab and ipilimumab treatment (NCT02060188)⁶⁵ and another phase Ib study of cobimetinib, atezolizumab and bevacizumab combination (NCT02876224)⁶⁶. In addition, several trials are investigating the combination of MEK inhibition with PD1 and chemotherapy (TABLE 2).

Bispecific antibody therapy. Bispecific antibodies are a new class of engineered agents with the ability to bind to two separate targets. CEA-TCB (also known as RG7802 or RO6958688) is a T cell bispecific antibody that simultaneously binds carcinoembryonic antigen (CEA) on tumour cells and CD3 on T cells, thus crosslinking cancer cells and T cells and leading to T cell engagement and activation independent of pre-existing immunity, T cell infiltration and tumour inflammation. CEA-TCB is being explored in two ongoing phase I studies: as a monotherapy (NCT02324257)⁶⁷ and in combination with atezolizumab (NCT02650713)⁶⁸. Following the data cut-off point in March 2017, encouraging clinical activity was reported in patients with metastatic MSS CRC treated with CEA-TCB monotherapy, which was enhanced by combination with atezolizumab⁶⁹. In the combination therapy group, the response rate was 18% ($n = 2$), and stable disease was observed in 7 patients (64%), for an overall disease control rate of 82%. Overall, toxic effects were manageable. CEA-TCB is the first T cell bispecific antibody to show efficacy in solid tumours and in MSS CRC in particular. These studies are ongoing⁶⁹.

Chemotherapy and antiangiogenic combinations. Preclinical data in lung cancer models demonstrated sensitization of tumours to checkpoint blockade through chemotherapy⁷⁰. The immunomodulatory potential of bevacizumab and antiangiogenic agents was observed in a trial in patients with melanoma that combined ipilimumab with bevacizumab treatment⁷¹. In this study, the addition of bevacizumab increased CD8⁺ T cell infiltration into the tumour compared with ipilimumab alone. Combinations of immune checkpoint blockade with bevacizumab treatment are under investigation, and preliminary results indicate activity. In preliminary data presented as an abstract from one trial of the

combination of atezolizumab plus bevacizumab with or without chemotherapy (NCT01633970), 14 patients with refractory pMMR-MSI-L CRC were treated with atezolizumab plus bevacizumab; 1 patient (7%) had an objective response, and 9 patients (64%) had stable disease^{72,73}. Subsequent correlative analysis showed that CD8⁺ T cell infiltration and PDL1 expression were increased in tumours following chemotherapy administration with

or without atezolizumab and bevacizumab⁷⁴. Several ongoing studies are investigating the combination of ICIs with antiangiogenic agents and chemotherapy (TABLE 2).

Radiotherapy combinations. As radiation causes DNA damage and probably generates an enlarged neoantigen repertoire for T cell priming, the immunogenic potential of radiotherapy is an active area of investigation⁷⁵.

Fig. 2 | The tumour microenvironment of dMMR-MSI-H and pMMR-MSI-L CRC. Colorectal cancers (CRCs) can be grouped into subtypes by distinguishing those that are mismatch-repair-deficient (dMMR) and have high levels of microsatellite instability (MSI-H) (termed dMMR-MSI-H) and those that are mismatch-repair-proficient (pMMR) and are microsatellite-stable or have low levels of microsatellite instability (MSI-L) (pMMR-MSI-L tumours). **a** | dMMR-MSI-H CRC shows prominent tumour-infiltrating lymphocytes that are programmed cell death 1 (PD1)⁺, accompanied by increased levels of programmed cell death 1 ligand 1 (PDL1)⁺ immune cells that are primarily present at the tumour–stroma interface. This tumour also shows loss of β_2 -microglobulin expression. pMMR-MSI-L CRC shows conventional morphology with no appreciable tumour-infiltrating lymphocytes. PD1⁺ lymphocytes in the stroma are rare, and no PDL1 labelling can be seen. This tumour has retained β_2 -microglobulin expression. Tissue sections are stained with haematoxylin and eosin. Positive immunohistochemistry staining is shown in brown. **b** | dMMR-MSI-H and pMMR-MSI-L CRCs have distinct tumour microenvironments. dMMR-MSI-H tumour cells are characterized by a high number of genomic mutations and, consequently, present mutated peptides on their major histocompatibility complex (MHC) class I molecules. Complexes of mutant peptides with MHC class I are recognized as foreign neoantigens, triggering immune cell priming and infiltration. Tumour-associated macrophages are an important component of the tumour microenvironment, influencing tumour growth and progression. dMMR-MSI-H CRCs are characterized by high levels of CD8⁺ T cell infiltration, T helper 1 (T_H1) CD4⁺ T cell infiltration and IFN γ secretion. To evade immune-mediated killing in this T cell-inflamed microenvironment, tumour cells strongly upregulate T cell inhibitory ligands, such as CD80 and CD86 of the B7 family and PDL1, which bind co-inhibitory receptors, such as cytotoxic T lymphocyte antigen 4 (CTLA4) and PD1. Immune checkpoint inhibitors (ICIs) exploit this pre-existing inflamed microenvironment by antagonizing T cell inhibitor signalling, exposing the tumour cells to cytotoxic destruction. By contrast, pMMR-MSI-L tumours do not generate immunostimulatory neoantigens and are characterized by T cell exclusion from the tumour. They express relatively low levels of immune-inhibitory ligands. These features suggest reasons for the differential response of dMMR-MSI-H and pMMR-MSI-L CRCs to ICIs and might be suitable as predictive biomarkers for patient selection. TCR, T cell receptor.

Interim results of a study investigating pembrolizumab combined with either radiofrequency ablation or external beam radiation (NCT02437071) in patients with CRC were reported in 2016. Of 22 patients who received external beam radiotherapy, 1 patient responded, and no responses were observed in the ablation arm. In patients with melanoma, tumour regression was demonstrated for the combination of radiotherapy with dual immune checkpoint blockade (anti-CTLA4 and PDL1)⁷⁶. Dual immune checkpoint blockade of CTLA4 and PDL1 in combination with radiotherapy or radiofrequency ablation is currently under investigation (NCT03122509)⁷⁷ (TABLE 2).

Biomarkers of response to immunotherapy

Mutational load and neoantigens. Presence of dMMR–MSI-H in colorectal tumours, as well as in other solid tumours, is a clear biomarker for potential response to immunotherapy, but identification of more precise and reliable predictive biomarkers continues to be an unmet clinical need. The relationship between mutational load and response to immunotherapy was initially described in melanoma for CTLA4-blocking antibody treatment and subsequently in NSCLC, in which an increased non-synonymous mutation (that is, mutations that alter the peptide sequence) burden was associated with improved response to the anti-PD1 antibody pembrolizumab^{26,78,79}. Mutational burden is certainly an important marker of

potential response, but high mutational burden alone does not seem to be sufficient for driving immunotherapy response. The nearly 20-times-higher mutation burden in dMMR–MSI-H compared with pMMR–MSI-L CRCs results in the generation of neo-epitopes, which are thought to trigger and be a target for host antitumour immune responses via T cell infiltration and cytolytic activity^{80–82}. Somatic mutational load and neoantigen density correlate with benefit from immune checkpoint blockade in many malignancies, with data suggesting that the high density of mutation-associated neoantigens (MANAs) generated results in T cell diversity⁸³. Furthermore, immune responses might be driven by specific generated MANAs. For example, high levels of clonal neoantigens seem to be markers of response, whereas subclonal neoantigens, usually resulting from tumour heterogeneity, might predict resistance to immunotherapy^{84,85}.

Interestingly, a high mutational load might not always be necessary to drive immunotherapy response. Evaluation of the presence of tumour-infiltrating CD3⁺CD8⁺ lymphocytes, through assignment of an immunoscore based on the density and the location of subsets of T cells, was prognostic of clinical outcome in patients with early-stage CRC, performing better than MSI and MMR status^{7,86,87}. High immunoscores were also reported in pMMR–MSI-L CRCs, raising the question of whether immunophenotyping might enable

Box 2 | Immune-related adverse events of checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) promote T cell activation by blocking negative regulators of T cell function¹⁴⁹. Because these regulators help keep the immune response in balance, blockade can lead to an unchecked immune response causing autoimmune-like adverse effects on normal organ systems, known as immune-related adverse events (irAEs). As ICIs have been used longest in patients with melanoma, adverse events have been studied most extensively in this patient population. Cytotoxic T lymphocyte antigen 4 (CTLA4) inhibitors tend to have more reported irAEs than programmed cell death 1 (PD1) and programmed cell death 1 ligand 1 (PDL1) inhibitors, but the combination of CTLA4 and PD1 inhibitors is associated with many more irAEs than each therapy alone²¹. The most common irAEs are dermatological, gastrointestinal, hepatic and endocrine events, but ICIs have also been reported to cause pulmonary, pancreatic, renal, cardiac, neurological, haematological and rheumatological adverse effects. The development of irAEs has been associated with better response to treatment and improved survival^{150,151}. irAEs occur frequently and are usually manageable; however, they can be severe and, rarely, fatal. Recognition and prompt treatment of these toxic effects are crucial. In the future, an increased understanding of their underlying mechanisms will help guide prevention and management to help decrease irAEs caused by these important cancer treatments.

Type of irAE	Symptoms	Incidence (%)		Median onset (weeks)	Treatment by severity		
		PD1 or PDL1	PD1 + CTLA4		Grade	Treatment	Stop ICI?
Dermatological	Rash and pruritus	15–20	40	3–6	1	Antihistamines and/or topical corticosteroids	No
					2	Topical corticosteroids	No
					≥3	Oral corticosteroids	Yes
Gastrointestinal	Diarrhoea and/or colitis	10–20	44	6–8	1	Conservative management	No
					2	Budesonide	Yes
					≥3	Corticosteroids	Yes
Hepatic	Abnormal enzyme levels	<5	18	8–12	≥3	Steroids	Yes
Endocrine	Fatigue, nausea and headache	10	NA	NA	NA	Routine corticosteroids not recommended	NA

NA, not available.

Table 1 | Ongoing trials in dMMR–MSI-H CRC

Checkpoint inhibitor	Trial type	Study treatment groups	Trial identifier
Atezolizumab	• Phase III • Stage 3 CRC	Adjuvant atezolizumab + FOLFOX versus FOLFOX alone	NCT02912559
	• Phase III • First-line metastatic CRC	Atezolizumab versus atezolizumab + FOLFOX + bevacizumab versus FOLFOX + bevacizumab	NCT02997228
Pembrolizumab	• Phase III • First-line metastatic CRC	Pembrolizumab versus standard-of-care chemotherapy	NCT02563002
	• Phase II • mCRC: refractory or ≥1 prior therapy	Pembrolizumab	NCT02460198
Avelumab	• Phase II • mCRC: >1 prior therapy	Avelumab	NCT03150706
Nivolumab ± ipilimumab	• Phase II • Refractory CRC	Nivolumab ± ipilimumab or daratumumab or anti-LAG3 antibody	NCT02060188
Atezolizumab	• Phase I • Locally advanced or metastatic solid tumours	• Atezolizumab + bevacizumab • Atezolizumab + bevacizumab + FOLFOX • Atezolizumab + carboplatin + paclitaxel • Atezolizumab + carboplatin + pemetrexed • Atezolizumab + carboplatin + nab-paclitaxel • Atezolizumab + nab-paclitaxel	NCT01633970

Data partially from¹⁵². Clinical trial details can be accessed at [ClinicalTrials.gov](https://clinicaltrials.gov) database. CRC, colorectal cancer; dMMR–MSI-H, mismatch-repair-deficient and microsatellite instability-high; FOLFOX, 5-fluorouracil, leucovorin and oxaliplatin; LAG3, lymphocyte activation gene 3 protein; mCRC, metastatic colorectal cancer.

prediction of immunotherapy benefit. Hence, combining the immunogenic features of the tumour microenvironment with mutational burden might be more precise in predicting immunotherapy response than either feature alone. Further validation of immunophenotyping as a predictive biomarker of immunotherapy response, specifically in metastatic disease, is needed for broad clinical utility.

POLE proofreading domain mutations. In addition to hypermutation of tumours caused by the dMMR–MSI-H pathway, large-scale genomic studies have revealed that tumours with mutations in the *POLE* exonuclease domain also result in a remarkably hypermutated somatic profile, which is commonly referred to as an ultramutated phenotype^{28,88}. *POLE* mutations in CRC have been well described. Recurrent mutations such as R286R, R286H, V411L and S459F are present in 1–2% of CRC tumours, with rare occurrence in mCRC⁸⁹. In contrast to dMMR–MSI-H tumours, the mutation rate in *POLE*-mutated tumours often exceeds 100 per 10⁶ DNA bases. In the majority of CRCs, these mutations are somatic events; however, germline mutations in the exonuclease domain of *POLE*, and to a lesser extent in that of *POLD1*, can also occur and are characterized by the presence of colonic polyposis, early-onset CRCs and potential risk of other cancers⁹⁰. *POLE*-mutated tumours are usually MSS, as the MMR system remains intact, although dMMR–MSI-H tumours in the setting of a *POLE* mutation, resulting from acquired somatic mutations in MMR genes, have been described^{91,92}. Similar to immunogenic dMMR–MSI-H tumours, *POLE*-mutated CRCs also display increased CD8⁺ lymphocyte infiltration, expression of cytotoxic T cell markers and effector cytokines and upregulation of

genes encoding immune checkpoints, such as PD1, PDL1 and CTLA4 (REF.⁹³). With respect to clinical characteristics, patients with *POLE*-mutated CRCs generally have an excellent prognosis, and these tumours are associated with early disease stage at presentation, male sex, right-sided tumour location and younger age at diagnosis⁹³. Given the similarly enhanced immunogenicity of *POLE*-mutated CRCs to dMMR–MSI-H CRCs, the therapeutic potential of immune checkpoint blockade in the subset of *POLE*-mutated CRCs is of particular interest and deserves further investigation. Clinical trials that include investigation of PD1 and PDL1 inhibitors in other *POLE*-mutated malignancies are currently ongoing (NCT02912572 (endometrial cancer)⁹⁴, NCT02899793 (endometrial cancer)⁹⁵ and NCT02658279 (malignant glioma)⁹⁶).

Other biomarkers for anti-PD1 therapy. Various other biomarkers of response to anti-PD1 therapy are currently being explored. Perhaps the most widely investigated marker is tumour PDL1 expression measured by immunohistochemical staining. Interestingly, in some tumour types, such as NSCLC, gastric cancer and gastroesophageal junction tumours, PDL1 expression might be useful as a predictive marker of response to anti-PD1 therapy^{22,97}, but in CRC, PDL1 expression was not found to be associated with response or survival in the registration studies^{51,98}. Markers of resistance to PD1 blockade, such as acquired mutations in *JAK1*, *JAK2* and *B2M*, have been discovered in patients with cancers such as melanoma⁹⁹, but their role in patients with CRC is not well defined. Truncating mutations in *B2M*, encoding β_2 -microglobulin, lead to impaired MHC class I antigen presentation and generation of immune escape variants that fail to elicit a T cell response. Although clinical data

Table 2 | Combination trials in pMMR–MSI-L CRC

Checkpoint inhibitor	Trial type	Combination treatment (target)	Trial identifier
Atezolizumab	• Phase I • mCRC	Cobimetinib (MEK) and bevacizumab (VEGFA)	NCT02876224
	• Randomized phase II • Refractory CRC	Capecitabine and bevacizumab (VEGFA)	NCT02873195
	• Phase III • mCRC	Cobimetinib (MEK) and regorafenib	NCT02788279
	• Phase II • First-line metastatic CRC	Cobimetinib (MEK)	NCT02291289
Durvalumab	• Phase I/II • Refractory CRC	Cediranib (VEGFR and KIT)	NCT02484404
Durvalumab ± tremelimumab	• Phase I • mCRC	Radiation	NCT02888743
	• Phase II • mCRC	Radiation or ablation	NCT03122509
	• Phase II • mCRC	Radiation	NCT03007407
Durvalumab	• Phase II • mCRC	Trametinib (MEK)	NCT03428126
	• Phase II • mCRC	Azacitidine (DNMT)	NCT02811497
Nivolumab	• Phase I/II • CRC and solid tumours	Epacadostat (IDO1)	NCT02327078
	• Phase I/II • Locally advanced rectal cancer	Chemoradiation	NCT02948348
	• Phase II • Refractory CRC	TAS-102	NCT0280546
Nivolumab ± ipilimumab	• Phase II • Refractory CRC	• Cobimetinib (MEK) • Daratumumab (CD38)	NCT02060188
	• Phase I/II • Metastatic pretreated CRC	Binimetinib (MEK)	NCT03271047
	• Phase II • CRC arm	Radiation	NCT03104439
	• Phase I/II • Metastatic pretreated CRC	Trametinib (MEK)	NCT03377361
	• Phase II • RAS-wild-type CRC	Panitumumab (EGFR)	NCT03442569
	• Phase II • Stage 1–3 CRC	Celecoxib (COX2)	NCT03026140
Pembrolizumab	• Phase I • Metastatic pretreated CRC	Oral azacitidine (DNMT) and romidepsin (HDAC1 and/or HDAC2)	NCT02512172
	• Phase Ib • mCRC	• Binimetinib (MEK) • ± FOLFOX or FOLFIRI	NCT03374254
	• Phase I/II • mCRC	Nintedanib (VEGFR, PDGFR and FGFR)	NCT02856425
	• Phase I/II • Refractory CRC and NSCLC	Azacitidine (DNMT) and epacadostat (IDO1)	NCT02959437
	• Phase Ib/II • Metastatic pretreated CRC	Cetuximab (EGFR)	NCT02713373
	• Phase II • GI tumours and CRC arm	Tumour-infiltrating lymphocytes, IL-2, cytoxan and fludarabine	NCT01174121
	• Phase II • mCRC	Binimetinib (MEK), FOLFOX and FOLFIRI	NCT03374254
	• Phase I • First-line metastatic CRC	FOLFOX and bevacizumab (VEGFA)	NCT03176264
PDR001	• Phase I • Metastatic pretreated CRC	Regorafenib (multikinase)	NCT03081494
Avelumab	Phase II	eFT508 (MNK)	NCT03258398

Data partially from¹⁵². Clinical trial details can be accessed at [ClinicalTrials.gov](https://clinicaltrials.gov) database. CRC, colorectal cancer; DNMT, DNA methyltransferase; FOLFIRI, 5-fluorouracil, leucovorin and irinotecan; FOLFOX, 5-fluorouracil, leucovorin and oxaliplatin; GI, gastrointestinal; IDO1, indoleamine 2,3-dioxygenase 1; mCRC, metastatic CRC; NSCLC, non-small-cell lung cancer; pMMR–MSI-L, mismatch-repair-proficient and microsatellite instability low.

suggest that patients with *B2M*-mutant dMMR–MSI-H CRCs have a favourable prognosis¹⁰⁰, interestingly, acquired *B2M* mutations were observed in tumours that developed resistance to pembrolizumab⁸. Mutations that inactivate JAK1 or JAK2 lead to both acquired as well as primary resistance to anti-PD1 therapy in melanoma^{99,101}, but their role in anti-PD1 response in CRC remains to be fully elucidated. Further, the aetiology of dMMR–MSI-H disease (germline versus somatic event) does not seem to be a predictive marker, as tumours arising in patients with Lynch syndrome have similar responses to anti-PD1 therapy as sporadic dMMR–MSI-H tumours⁸. Various groups have developed gene expression signatures associated with intratumoural cytotoxic T cell infiltration, but these signatures have not been explored as predictive biomarkers in the context of ICI clinical trials in CRC^{102,103}.

Adjuvant and neoadjuvant therapy

Only ~4% of patients with mCRC have dMMR–MSI-H tumours, but this phenotype is present in 12% of patients with stage 3 CRCs, in whom adjuvant chemotherapy (fluorouracil plus oxaliplatin) is routinely administered. In an effort to determine the potential efficacy of immunotherapy in the adjuvant treatment of early-stage CRC, a randomized phase III trial is evaluating the combination of chemotherapy and atezolizumab compared with chemotherapy only in 700 patients with stage 3 dMMR–MSI-H colon cancer (NCT02912559)^{104,105}. In the experimental arm, patients receive FOLFOX plus atezolizumab for 6 months followed by atezolizumab monotherapy for 6 months. The primary trial end point is disease-free survival, and overall survival and incidence of adverse events are the secondary end points.

Exciting preliminary results from an ongoing single-arm study of short-term combination nivolumab and ipilimumab in patients with resectable, early-stage CRC were presented at the 2018 ESMO meeting¹⁰⁶. The primary end points of this study are safety and feasibility, and the secondary end points include pathological response. All patients underwent surgery a maximum of 6 weeks after informed consent. All of the seven patients with dMMR–MSI-H tumours achieved a major pathological response, and four of these (57%) had complete responses. In the eight patients with pMMR–MSI-L tumours, no major pathological responses were noted, but significant increases in T cell infiltration were seen after treatment in both dMMR–MSI-H ($P=0.0009$) and pMMR–MSI-L ($P=0.018$) tumours. If these results are corroborated in expanded cohorts with long-term follow-up, they raise the intriguing question whether surgical resection, which has long been the mainstay of curative-intent treatment for early-stage CRC, might be safely avoided in a select subgroup of patients with dMMR–MSI-H CRC.

Primary prevention

In addition to opportunities in the treatment of existing tumours, the advent of immunotherapy also provides the possibility of precision prevention oncology for individuals with germline mutations in MMR genes, diagnostic of Lynch syndrome. Patients with

Lynch syndrome have an increased lifetime risk of several malignancies, for example, CRC and endometrial, ovarian, gastric, pancreatic and ureteral cancer¹⁰⁷. Cancer screening or risk-reducing surgical interventions, such as colonoscopy or prophylactic hysterectomy and oophorectomy, are part of the management considerations for these individuals¹⁰⁸, but immune-response-based prevention is also being explored for risk reduction. The applicability of ICIs, including anti-PD1 or anti-PDL1 agents, for cancer prevention is currently limited by drug toxicity; however, other immunological intervention strategies including vaccines are being explored. Defective MMR results in the accumulation of frameshift mutations at microsatellite tracts, with the generation of frameshift-mutation-derived peptides (FSPs) when the mutation is in the coding regions of the genome¹⁰⁹. Compared with neoantigens resulting from single-nucleotide alterations, FSP-based neoantigens can encompass long antigenic amino acid stretches that contain multiple immunologically relevant neoepitopes and can be highly immunogenic^{110,111}. Given that microsatellite tracts occur at specific loci, FSPs have predictable sequences, providing an opportunity for targeted vaccine development strategies. For example, vaccination with three commonly mutated FSP antigens was tested in a phase I/IIa trial in patients with stage 3 or 4 dMMR–MSI-H CRC following completion of standard chemotherapy¹¹². In 22 enrolled patients, FSP-specific immune responses were induced in all vaccinated patients, with 1 heavily pretreated patient with bulky metastases demonstrating stable disease for 7 months. Although these are early data, FSP vaccination is a promising approach for improving the prognosis of patients with dMMR–MSI-H cancers in the adjuvant setting or potentially for cancer prevention in individuals with Lynch mutations but without a cancer diagnosis.

Beyond PD1 blockade

T cell checkpoint modulation. PD1 blockade is currently the only FDA-approved immunotherapeutic strategy for CRC, but PD1–PDL1 interaction is only one of several immune checkpoint interactions that regulate T cell activation in the tumour microenvironment (FIG. 2). On the basis of promising preclinical data^{113–116}, molecules that block other T cell checkpoint inhibitors (for example, T cell immunoglobulin mucin receptor 3 (TIM3; also known as HAVCR2), lymphocyte activation gene 3 protein (LAG3) and T cell immunoreceptor with Ig and ITIM domains (TIGIT)) are in clinical trials for various advanced malignancies, including CRC¹¹⁷ (TABLE 3). Complementing immune checkpoint blockade, molecules that promote T cell differentiation, survival and proliferation are being studied either as single agents or in combination with checkpoint blockade (FIG. 3; TABLE 3). Several of these molecules are antibody agonists of the co-stimulatory group of the TNF receptor superfamily (for example, CD27, OX40 (also known as CD134), 4-1BB (also known as CD137), glucocorticoid-induced TNF receptor-related gene (GITR; also known as CD357) and CD40)^{118–120}.

Table 3 | Next-generation immune checkpoint modulator studies in CRC

Drug	Target	Trial type	Trial identifier
Antagonists of T cell inhibition			
TSR022 ± anti-PD1 antibody	• TIM3 • PD1	• Phase I • Advanced solid tumours	NCT02817633
LY3321367 ± LY3300054	• TIM3 • PDL1	• Phase I • Advanced solid tumours	NCT03099109
MBG453 ± PDR001	• TIM3 • PD1	• Phase I/II • Advanced solid tumours	NCT02608268
Relatlimab ± nivolumab	• LAG3 • PD1	• Phase I/II • Advanced solid tumours	• NCT01968109 • NCT02966548
TSR033 ± anti-PD1 antibody	• LAG3 • PD1	• Phase I • Advanced solid tumours	NCT03250832
IMP321	LAG3	• Phase I • Advanced solid tumours	• NCT03252936 • NCT02676869
REGN3767 ± REGN2810	• LAG3 • PD1	• Phase I • Advanced solid tumours	NCT03005782
MGD013	• LAG3 and PD1 • Bispecific antibody	• Phase I • Advanced solid tumours • Haematologic neoplasms	NCT03219268
OMP313M32	TIGIT	• Phase I • Advanced solid tumours	NCT03119428
MTIG7192A ± atezolizumab	TIGIT	• Phase I • Advanced solid tumours	NCT02794571
Agonists of T cell activation			
TRX518	GITR	• Phase I • Unresectable stage 3–4 solid tumours	NCT01239134
GWN323 ± PDR001	• GITR • PD1	• Phase I • Advanced solid tumours	NCT02740270
MEDI1873	GITR	• Phase I • Advanced solid tumours	NCT02583165
OMP336B11	GITR	• Phase I • Locally advanced or metastatic solid tumours	NCT03295942
INCAGN01876 ± nivolumab or ipilimumab	• GITR • PD1 • CTLA4	• Phase I/II • Advanced solid tumours	• NCT02697591 • NCT03126110
Anti-OX40 + tetanus vaccine + keyhole limpet antigen	OX40	• Phase I • Advanced cancer	NCT01644968
MEDI6469	OX40	• Phase I • Metastatic colorectal cancer	NCT02559024
MOXR0916 + atezolizumab	• OX40 • PDL1	• Phase Ib • Locally advanced or metastatic solid tumours	NCT02410512
MEDI6383 + MEDI14736	• OX40 • PDL1	• Phase I • Recurrent and/or metastatic solid tumours	NCT02221960
MEDI0562 ± durvalumab or tremelimumab	• OX40 • PDL1 • CTLA4	• Phase I • Advanced solid tumours	• NCT02318394 • NCT02705482
GSK3174998 ± Pembrolizumab	OX40	• Phase I • Advanced solid tumours	NCT02528357
INCAGN01949 ± nivolumab and/or ipilimumab	• OX40 • PD1 • CTLA4	• Phase I • Advanced solid tumours	• NCT02923349 • NCT03241173
PF05082566 ± MK-3457	• 4-1BB • PD1	• Phase I • Advanced solid tumours	NCT02179918
PF04518600 ± PF05082566	• OX40 • 4-1BB	• Phase I • Neoplasms	NCT02315066

Table 3 (cont.) | Next-generation immune checkpoint modulator studies in CRC

Drug	Target	Trial type	Trial identifier
Agonists of T cell activation (cont.)			
Avelumab ± PF04518600 or PD-0360324 or utomilumab	• PDL1 • OX40 • M-CSF • 4-1BB	• Phase II • Advanced malignancies	NCT02554812
JTX2011 ± nivolumab	• ICOS • PD1	• Phase I • Advanced solid tumours	NCT02904226
GSK3359609 ± pembrolizumab	• ICOS • PD1	• Phase I/II • Advanced solid tumours	NCT02723955
SEA-CD40 ± pembrolizumab	• CD40 • PD1	• Phase I • Advanced solid tumours	NCT02376699
APX005M ± nivolumab	• CD40 • PD1	• Phase I/II • Advanced solid tumours	• NCT02482168 • NCT03123783
Chi Lob 7/4	CD40	• Phase I • Advanced cancer	NCT01561911
ADC1013	CD40	• Phase I • Advanced solid tumours	NCT02379741
CDX1140	CD40	• Phase I • Advanced solid tumours	NCT03329950
JNJ64457107	CD40	• Phase I • Advanced solid tumours	NCT02829099
RO7009789 + atezolizumab	CD40	• Phase I • Advanced solid tumours	NCT02304393
CP870,893	CD40	• Phase I • Advanced solid tumours	NCT02225002
Varlilumab + nivolumab	• CD27 • PD1	• Phase I/II • Advanced solid tumours	NCT02335918
ARGX110	CD70	• Phase I/II • Advanced solid tumours	NCT01813539

Clinical trial details can be accessed at [ClinicalTrials.gov](https://clinicaltrials.gov) database. CRC, colorectal cancer; CTLA4, cytotoxic T lymphocyte antigen 4; GITR, glucocorticoid-induced TNF receptor-related gene; ICOS, inducible T cell co-stimulator; LAG3, lymphocyte activation gene 3 protein; PD1, programmed cell death 1; PDL1, programmed cell death 1 ligand 1; TIGIT, T cell immunoreceptor with Ig and ITIM domains; TIM3, T cell immunoglobulin mucin receptor 3.

Cellular immunotherapy. Adoptive cell therapy (ACT) is an exciting emerging modality for treating CRC. ACT involves the collection of T cells from tumours, lymph nodes or peripheral blood of patients, in vitro expansion and transfer of tumour-destroying T cells into patients¹²¹. In vitro, tumour-targeting T cells can be selected for binding to tumour antigens or engineered to express chimeric antigen receptors (CARs) that improve T cell recognition of tumour proteins other than MHC class I¹²². T cells can also be engineered to secrete cytokines or express immunostimulatory ligands that further potentiate their efficacy (termed armoured CAR T cells)¹²³, for example, IL-12, IL-7 receptor and lipid nanoparticles containing IL-15 (REF.¹²⁴).

Several groups have investigated CEA, which is overexpressed in many CRCs, as a target for ACT^{125–127}. In a small study, CAR T cells targeting CEA were administered to three patients with mCRC¹²⁵. One of the patients had an objective response in lung and liver metastases, and serum CEA levels declined in all three patients. However, all three patients developed severe colitis as a dose-limiting toxic effect. In another study, 7 of 10 patients with heavily treated mCRC had stable disease 4 weeks after CAR T cell infusion, and 2 patients experienced tumour shrinkage¹²⁷. At 30 weeks,

2 patients continued to have stable disease. In this study, treatment was well tolerated, with no reports of colitis.

In an intriguing advance, researchers in one study collected TILs from a patient with lung metastases from KRAS^{G12D}-mutant CRC and selected clonal T cell cultures with the highest specific CD8⁺ T cell reactivity to KRAS^{G12D} for adoptive transfer into the patient¹²⁸. All seven lung metastases regressed, and the patient had a partial response according to Response Evaluation Criteria in Solid Tumours (RECIST) at 9 months, when 1 lesion progressed. This lesion was resected, and the patient was clinically disease free for 3 months following resection. This early success suggests an exciting new strategy for therapeutically targeting mutant transcription factors that drive CRC growth, which has been difficult to achieve to date.

To date, CAR T cell therapy has been successfully used in the treatment of B cell malignancies, in which treatment with CAR T cells targeting the B cell antigen CD19 resulted in complete responses and has gained approval from the FDA and the EMA Committee for Medicinal Products for Human Use^{129,130}. However, the applicability of CAR T cell therapy to solid tumours, such as CRC, remains to be proved. Concerns regarding the limited extent of infiltration of adoptively transferred T cells into

the dense microenvironment of solid tumours and potential safety concerns related to systemic cytokine release syndrome and on-target-off-tumour effects against normal epithelial cells remain to be resolved^{131,132}. In the

real-world clinical setting, the feasibility and affordability of highly individualized, technically sophisticated cell manipulation approaches also present a challenge.

Other approaches. Vaccines and immunostimulatory cytokines were first investigated as potential CRC immunotherapeutics >30 years ago but have not changed clinical practice to date^{133,134}. The efficacy of PD1 blockade in dMMR-MSI-H CRC has provided definitive evidence of the clinical utility of immunotherapy and, hence, has renewed interest in these approaches, both as single agents and in combination with PD1 inhibition. Several trials are ongoing that investigate oncolytic bacteria or viruses or peptide, tumour, virus or dendritic cell antigens in combination with various adjuvants with the goal of improving tumour immunogenicity in the adjuvant and metastatic settings in CRC and other solid tumours. As crucial drivers of inflammation conducive to tumour progression, tumour-associated macrophages are attractive targets to complement current PD1-targeted and PDL1-targeted ICIs¹³⁵. A key target is colony-stimulating factor 1 receptor (CSF1R), which is expressed on mononuclear phagocytes and dimerizes upon binding to colony-stimulating factor 1 (CSF1) or IL-34, activating macrophage proliferation and function^{136,137}. CSF1R-specific inhibitors and other macrophage modulators are currently being investigated in clinical trials for solid tumours including mCRC¹³⁸, either as single agents or in combination with chemotherapy or ICIs (for example, NCT02777710)¹³⁹.

Conclusions

Owing to their high mutation burden, dMMR-MSI-H CRCs present peptide neoantigens on MHC class I molecules and, therefore, prime T cells to recognize them as foreign. Building on initial successes in other heavily mutated tumour types such as melanoma, monoclonal antibodies that block immune checkpoints prevent T cell anergy, promote cytotoxic CD8⁺ T cell destruction of tumours and can induce long-term durable responses in some patients with an increasing range of malignancies. This strategy has proved remarkably successful in the small subset of patients with mCRC whose tumours are characterized by a dMMR-MSI-H phenotype, resulting in FDA approval in 2017 of two checkpoint inhibitors: pembrolizumab and nivolumab for the treatment of dMMR-MSI-H mCRC. Indeed, pembrolizumab is now FDA-approved for the treatment of all dMMR-MSI-H metastatic solid tumours, becoming the first biomarker-based, tumour type-agnostic treatment for cancer⁸.

The success of PD1 inhibitors in achieving durable responses in some patients with dMMR-MSI-H CRC heralds the dawn of a new era in the treatment of patients with a subtype of mCRC. However, not all patients with dMMR-MSI-H respond to current ICIs. Further insight into the mechanisms of immunotherapy resistance is needed, and biomarkers that predict therapy response in patients with dMMR-MSI-H CRC are required. Beyond dMMR-MSI-H CRC, the critical challenge is to develop strategies for targeting pMMR-MSI-L CRCs, which constitute the vast majority of mCRC cases and for which current immunotherapy approaches have been

Fig. 3 | Targets of select immunomodulatory drugs in clinical trials for metastatic CRC. Many drugs that modulate immune checkpoints are currently in clinic trials in patients with colorectal cancer (CRC) (TABLE 3). These agents act as antagonists of T cell inhibitory signals or agonists of T cell activating signals by targeting ligands expressed on the surface of tumour cells or antigen-presenting cells, receptors on the surface of T cells or metabolites and cytokines that serve as paracrine signalling molecules. 4-1BBL, 4-1BB ligand; CD40L, CD40 ligand; CTLA4, cytotoxic T lymphocyte antigen 4; ICOS, inducible T cell co-stimulator; ICOSL, inducible T cell co-stimulator ligand; IDO, indoleamine 2,3-dioxygenase; GITR, glucocorticoid-induced TNF receptor-related gene; GITRL, glucocorticoid-induced TNF receptor-related gene ligand; LAG3, lymphocyte activation gene 3 protein; MHC, major histocompatibility complex; OX40L, OX40 ligand; PD1, programmed cell death 1; PDL1, programmed cell death 1 ligand 1; TIGIT, T cell immunoreceptor with Ig and ITIM domains; TIM3, T cell immunoglobulin mucin receptor 3.

largely unsuccessful. The convergence of progress in several scientific and medical fields is providing unprecedented insight into the relationship between cancer cells and their immune microenvironment, including histopathology, genomics, immune profiling, single-cell transcriptomics, TCR characterization, neoantigen prediction, ex vivo T cell manipulation, the growing armamentarium of immune checkpoint modulators,

cellular therapies and vaccines, and cutting-edge clinical trials providing real-world human data on mechanisms of immune resistance. Hopefully, this surge of knowledge will lead to improved pharmacological strategies to overcome primary resistance to immunotherapy of pMMR–MSI-L CRC.

Published online 18 March 2019

1. Garborg, K. et al. Current status of screening for colorectal cancer. *Ann. Oncol.* **24**, 1963–1972 (2013).
2. Siegel, R., Desantis, C. & Jemal, A. Colorectal cancer statistics, 2014. *CA Cancer J. Clin.* **64**, 104–117 (2014).
3. Edwards, B. K. et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. *Cancer* **116**, 544–573 (2010).
4. Sargent, D. et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. *J. Clin. Oncol.* **27**, 872–877 (2009).
5. Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat. Genet.* **51**, 202–206 (2019).
6. Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. *Ann. Oncol.* **30**, 44–56 (2019).
7. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science* **313**, 1960–1964 (2006).
8. Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* **357**, 409–413 (2017).
9. Pages, F. et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. *N. Engl. J. Med.* **353**, 2654–2666 (2005).
10. Galon, J., Fridman, W. H. & Pages, F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. *Cancer Res.* **67**, 1883–1886 (2007).
11. Khalil, D. N., Smith, E. L., Brentjens, R. J. & Wolchok, J. D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. *Nat. Rev. Clin. Oncol.* **13**, 273–290 (2016).
12. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoeediting: integrating immunity's roles in cancer suppression and promotion. *Science* **331**, 1565–1570 (2011).
13. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. *Science* **348**, 56–61 (2015).
14. Townsend, S. E. & Allison, J. P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. *Science* **259**, 368–370 (1993).
15. Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. *Cancer Discov.* **8**, 1069–1086 (2018).
16. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N. Engl. J. Med.* **363**, 711–723 (2010).
17. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N. Engl. J. Med.* **364**, 2517–2526 (2011).
18. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N. Engl. J. Med.* **372**, 320–330 (2015).
19. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. *N. Engl. J. Med.* **372**, 2521–2532 (2015).
20. Schadendorf, D. et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. *J. Clin. Oncol.* **33**, 1889–1894 (2015).
21. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N. Engl. J. Med.* **373**, 23–34 (2015).
22. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N. Engl. J. Med.* **372**, 2018–2028 (2015).
23. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N. Engl. J. Med.* **373**, 123–135 (2015).
24. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N. Engl. J. Med.* **373**, 1627–1639 (2015).
25. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. *Nature* **500**, 415–421 (2013).
26. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science* **348**, 124–128 (2015).
27. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. *Science* **348**, 69–74 (2015).
28. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* **487**, 330–337 (2012).
29. Salipante, S. J., Scroggins, S. M., Hampel, H. L., Turner, E. H. & Pritchard, C. C. Microsatellite instability detection by next generation sequencing. *Clin. Chem.* **60**, 1192–1199 (2014).
30. Niu, B. et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. *Bioinformatics* **30**, 1015–1016 (2014).
31. Middha, S. et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. *JCO Precis. Oncol.* **1**, 1–17 (2017).
32. Hause, R. J., Pritchard, C. C., Shendure, J. & Salipante, S. J. Classification and characterization of microsatellite instability across 18 cancer types. *Nat. Med.* **22**, 1342–1350 (2016).
33. Giardiello, F. M. et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. *Gastroenterology* **147**, 502–526 (2014).
34. Alexander, J. et al. Histopathological identification of colon cancer with microsatellite instability. *Am. J. Pathol.* **158**, 527–535 (2001).
35. Dolcetti, R. et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. *Am. J. Pathol.* **154**, 1805–1813 (1999).
36. Smyrk, T. C., Watson, P., Kaul, K. & Lynch, H. T. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. *Cancer* **91**, 2417–2422 (2001).
37. Young, J. et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. *Am. J. Pathol.* **159**, 2107–2116 (2001).
38. Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. *Nat. Immunol.* **14**, 1014–1022 (2013).
39. Lloa, N. J. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. *Cancer Discov.* **5**, 43–51 (2015).
40. Graham, D. M. & Appelman, H. D. Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. *Mod. Pathol.* **3**, 332–335 (1990).
41. Jass, J. R. et al. Morphology of sporadic colorectal cancer with DNA replication errors. *Gut* **42**, 673–679 (1998).
42. Nagorsen, D. et al. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T cell response against tumor-associated antigens and survival. *J. Transl. Med.* **5**, 62 (2007).
43. Boland, C. R. et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res.* **58**, 5248–5257 (1998).
44. Popat, S., Hubner, R. & Houlston, R. S. Systematic review of microsatellite instability and colorectal cancer prognosis. *J. Clin. Oncol.* **23**, 609–618 (2005).
45. Venderbosch, S. et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. *Clin. Cancer Res.* **20**, 5322–5330 (2014).
46. Chung, K. Y. et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. *J. Clin. Oncol.* **28**, 3485–3490 (2010).
47. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N. Engl. J. Med.* **366**, 2455–2465 (2012).
48. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N. Engl. J. Med.* **366**, 2443–2454 (2012).
49. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. *J. Clin. Oncol.* **28**, 3167–3175 (2010).
50. Lipson, E. J. et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. *Clin. Cancer Res.* **19**, 462–468 (2013).
51. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N. Engl. J. Med.* **372**, 2509–2520 (2015).
52. Le, D. T. et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. *J. Clin. Oncol.* **34**, 103 (2016).
53. Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncol.* **18**, 1182–1191 (2017).
54. Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. *J. Clin. Oncol.* **36**, 773–779 (2018).
55. Andre, T. L. et al. Nivolumab+ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): first report of the full cohort from CheckMate-142. *J. Clin. Oncol.* **36** (Suppl.), 553 (2018).
56. Lenz, H.-J. J. et al. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). *Ann. Oncol.* **29** (Suppl.), LBA18_PR (2018).
57. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02997228> (2019).
58. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02563002> (2018).
59. Liu, L. et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. *Clin. Cancer Res.* **21**, 1639–1651 (2015).
60. Ebert, P. J. R. et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. *Immunity* **44**, 609–621 (2016).
61. Bendell, J. C. et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). *J. Clin. Oncol.* **34** (Suppl.), 3502 (2016).
62. Bendell, J. C. B. et al. A phase 1b study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC). *J. Clin. Oncol.* **36**, 560 (2018).

63. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02788279> (2019).
64. Bendell, J. et al. Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy versus regorafenib in chemotherapy-refractory metastatic colorectal cancer. *Ann. Oncol.* **29**, LBA-004 (2018).
65. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02060188> (2018).
66. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02876224> (2019).
67. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02324257> (2019).
68. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02650713> (2019).
69. Segal, N. H. S. et al. Phase-I studies of the novel carcinoembryonic antigen T cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab. *Ann. Oncol.* **28** (Suppl. 5), 122–141 (2017).
70. Pfirschke, C. et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. *Immunity* **44**, 343–354 (2016).
71. Hodi, F. S. et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. *Cancer Immunol. Res.* **2**, 632–642 (2014).
72. Hochster, H. S. B. et al. Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). *J. Clin. Oncol.* **35** (Suppl.), 673 (2017).
73. Bendell, J. C. et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). *J. Clin. Oncol.* **33**, 704 (2015).
74. Wallin, J. et al. Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma. *Cancer Res.* **76**, 2651 (2016).
75. Park, S. S. et al. PD-1 restrains radiotherapy-induced abscopal effect. *Cancer Immunol. Res.* **3**, 610–619 (2015).
76. Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature* **520**, 373–377 (2015).
77. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT03122509> (2018).
78. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N. Engl. J. Med.* **371**, 2189–2199 (2014).
79. Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science* **350**, 207–211 (2015).
80. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* **515**, 568–571 (2014).
81. Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. *Nature* **520**, 692–696 (2015).
82. Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. *Cell* **160**, 48–61 (2015).
83. Li, B. et al. Landscape of tumor-infiltrating T cell repertoire of human cancers. *Nat. Genet.* **48**, 725–732 (2016).
84. McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. *Science* **351**, 1463–1469 (2016).
85. Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. *Cancer Discov.* **7**, 264–276 (2017).
86. Mlecnik, B. et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. *Immunity* **44**, 698–711 (2016).
87. Pages, F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet* **391**, 2128–2139 (2018).
88. Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. *Nat. Med.* **21**, 1350–1356 (2015).
89. Yaeger, R. et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. *Cancer Cell* **33**, 125–136 (2018).
90. Palles, C. et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. *Nat. Genet.* **45**, 136–144 (2013).
91. Elsayed, F. A. et al. Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. *Eur. J. Hum. Genet.* **23**, 1080–1084 (2015).
92. Jansen, A. M. et al. Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers. *Eur. J. Hum. Genet.* **24**, 1089–1092 (2016).
93. Domingo, E. et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. *Lancet Gastroenterol. Hepatol.* **1**, 207–216 (2016).
94. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02912572> (2018).
95. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02899793> (2018).
96. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02658279> (2019).
97. Hersom, M. & Jorgensen, J. T. Companion and complementary diagnostics-focus on PD-L1 expression assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. *Ther. Drug Monit.* **40**, 9–16 (2017).
98. André, T. et al. Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142. *Ann. Oncol.* **28**, 484PD (2017).
99. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. *N. Engl. J. Med.* **375**, 819–829 (2016).
100. Koelzer, V. H., Baker, K., Kassahn, D., Baumhoer, D. & Zlobec, I. Prognostic impact of beta-2-microglobulin expression in colorectal cancers stratified by mismatch repair status. *J. Clin. Pathol.* **65**, 996–1002 (2012).
101. Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. *Cancer Discov.* **7**, 188–201 (2017).
102. Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity* **39**, 782–795 (2013).
103. Chifman, J., Pullikuth, A., Chou, J. W., Bedognetti, D. & Miller, L. D. Conservation of immune gene signatures in solid tumors and prognostic implications. *BMC Cancer* **16**, 911 (2016).
104. Sinicrope, F. A. O. et al. Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502). *J. Clin. Oncol.* **35**, TPS3630 (2017).
105. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02912559> (2019).
106. Grootsholten, C. et al. Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer. *Ann. Oncol.* **29**, LBA37_PR (2018).
107. Watson, P. et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. *Int. J. Cancer* **123**, 444–449 (2008).
108. Syngal, S. et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am. J. Gastroenterol.* **110**, 223–262; quiz 263 (2015).
109. Schwitalle, Y. et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. *Gastroenterology* **134**, 988–997 (2008).
110. Kloor, M. & von Knebel Doeberitz, M. The immune biology of microsatellite-unstable cancer. *Trends Cancer* **2**, 121–133 (2016).
111. Reuschenbach, M. et al. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. *Fam. Cancer* **9**, 173–179 (2010).
112. Doeberitz, M. v. K. et al. Frameshift peptide neoantigens as vaccine targets in microsatellite-unstable cancers. *Cancer Immunol. Res.* **4**, A006 (2016).
113. Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape. *Cancer Res.* **72**, 917–927 (2012).
114. Grosso, J. F. et al. LAG-3 regulates CD8+T cell accumulation and effector function in murine self- and tumor-tolerance systems. *J. Clin. Invest.* **117**, 3383–3392 (2007).
115. Ngiew, S. F. et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. *Cancer Res.* **71**, 3540–3551 (2011).
116. Sakuiishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. *J. Exp. Med.* **207**, 2187–2194 (2010).
117. Anderson, A. C., Joller, N. & Kuchroo, V. K. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. *Immunity* **44**, 989–1004 (2016).
118. Ward-Kavanagh, L. K., Lin, W. W., Sedy, J. R. & Ware, C. F. The TNF receptor superfamily in co-stimulating and co-inhibitory responses. *Immunity* **44**, 1005–1019 (2016).
119. Croft, M., Benedict, C. A. & Ware, C. F. Clinical targeting of the TNF and TNFR superfamily. *Nat. Rev. Drug Discov.* **12**, 147–168 (2013).
120. Brenner, D., Blaser, H. & Mak, T. W. Regulation of tumour necrosis factor signalling: live or let die. *Nat. Rev. Immunol.* **15**, 362–374 (2015).
121. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. *Science* **348**, 62–68 (2015).
122. Miliotou, A. N. & Papadopoulos, L. C. CAR T cell therapy: a new era in cancer immunotherapy. *Curr. Pharm. Biotechnol.* **19**, 5–18 (2018).
123. Yeku, O. O. & Brentjens, R. J. Armored CAR T cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T cell anti-tumour efficacy. *Biochem. Soc. Trans.* **44**, 412–418 (2016).
124. Shum, T., Kruse, R. L. & Rooney, C. M. Strategies for enhancing adoptive T cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. *Expert Opin. Biol. Ther.* **18**, 653–664 (2018).
125. Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. *Mol. Ther.* **19**, 620–626 (2011).
126. Katz, S. C. et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T cell therapy for CEA+ liver metastases. *Clin. Cancer Res.* **21**, 3149–3159 (2015).
127. Zhang, C. et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. *Mol. Ther.* **25**, 1248–1258 (2017).
128. Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. *N. Engl. J. Med.* **375**, 2255–2262 (2016).
129. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N. Engl. J. Med.* **371**, 1507–1517 (2014).
130. Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B cell lymphoma and indolent B cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. *J. Clin. Oncol.* **33**, 540–549 (2015).
131. Johnson, L. A. & June, C. H. Driving gene-engineered T cell immunotherapy of cancer. *Cell Res.* **27**, 38–58 (2017).
132. Newick, K., O'Brien, S., Moon, E. & Albelda, S. M. CAR T cell therapy for solid tumors. *Annu. Rev. Med.* **68**, 139–152 (2017).
133. Hoover, H. C. Jr. et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. *J. Clin. Oncol.* **11**, 390–399 (1993).
134. Harris, J. E. et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. *J. Clin. Oncol.* **18**, 148–157 (2000).
135. Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. *Nat. Rev. Clin. Oncol.* **14**, 399–416 (2017).

136. Lin, H. et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. *Science* **320**, 807–811 (2008).
137. Otero, K. et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. *Nat. Immunol.* **10**, 734–743 (2009).
138. Ngambenjawong, C., Gustafson, H. H. & Pun, S. H. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. *Adv. Drug Deliv. Rev.* **114**, 206–221 (2017).
139. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02777710> (2019).
140. Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. *Nat. Rev. Cancer* **4**, 71–78 (2004).
141. Gordon, S. R. et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. *Nature* **545**, 495–499 (2017).
142. Arlauckas, S. P. et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. *Sci. Transl. Med.* **9**, eaal3604 (2017).
143. Ablasser, A. et al. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. *Nature* **498**, 380–384 (2013).
144. Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. *Immunity* **41**, 830–842 (2014).
145. Corrales, L. et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. *Cell Rep.* **11**, 1018–1030 (2015).
146. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02675439> (2018).
147. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT03010176> (2019).
148. US National Library of Medicine. *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT03172936> (2018).
149. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. *Nat. Immunol.* **3**, 991–998 (2002).
150. Freeman-Keller, M. et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. *Clin. Cancer Res.* **22**, 886–894 (2016).
151. Lo, J. A., Fisher, D. E. & Flaherty, K. T. Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. *JAMA Oncol.* **1**, 1340–1341 (2015).
152. Boland, P. M. & Ma, W. W. Immunotherapy for colorectal cancer. *Cancers* **9**, 50 (2017).

Author contributions

K.G., Z.K.S., A.C., R.B.M. and N.H.S. researched data for the article. K.G., Z.K.S., A.C., J.S., N.H.S. and L.A.D. made substantial contributions to discussion of the article content. K.G., Z.K.S., A.C., R.B.M., J.S. and N.H.S. wrote the manuscript. K.G., Z.K.S., N.H.S. and L.A.D. reviewed and/or edited the manuscript before submission.

Competing interests

R.B.M. is a speaker for Vindico and Medscape and a consultant for Roche. N.H.S. receives research funding from Roche/Genentech, Merck, Bristol-Myers Squibb, MedImmune/AstraZeneca and Incyte and is on the advisory board of Roche/Genentech, Merck, Bristol-Myers Squibb, MedImmune/AstraZeneca, Boehringer Ingelheim and Pfizer. L.A.D. is a founder and shareholder of PapGene and Personal Genome Diagnostics (PGDx) and a consultant for Merck, PGDx and Phoremost. PapGene and PGDx, as well as other companies, have licensed technologies from Johns Hopkins University on which L.A.D. is an inventor. These licences and relationships are associated with equity or royalty payments to L.A.D. L.A.D. is also a member of the board of directors of PGDx and Jounce Therapeutics. The terms of these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies. K.G., Z.K.S., A.C. and J.S. declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reviewer information

Nature Reviews Gastroenterology & Hepatology thanks T. André, J. Lee and the other anonymous reviewer(s), for their contribution to the peer review of this work.

RELATED LINKS

ClinicalTrials.gov database: <https://clinicaltrials.gov/ct2/home>